M2 EQUITYBITES-August 23, 2017-InfraREIT passes early termination of Hart-Scott-Rodino Act
waiting period for planned exchange agreement
The principal federal antitrust acts are the Sherman Act, (1) the Clayton Act, (2) the Federal Trade Commission Act, (3) the Robinson-Patman Act, (4) and the Hart-Scott-Rodino Act
These include the Washington Utilities and Transportation Commission, the Oregon Public Utility Commission and the various jurisdictions under which MDU Resources' utility divisions operate, as well as clearance under the Hart-Scott-Rodino Act
and the satisfaction of other customary closing conditions.
The acquisition was approved by the Rhode Island Division of Public Utilities and Carriers on July 25, 2006 and received clearance under the federal Hart-Scott-Rodino Act
The merger is subject to approval by shareholders of both companies, Hart-Scott-Rodino Act
, as well as various state and federal regulatory authorities, including the Federal Regulatory Commission, the Illinois Commerce Commission and the Public Service Commission of Wisconsin.
The acquisition closed following receipt of the approval of the limited partners of Titan Energy Partners LP on May 15, 2005, and the expiration of the waiting period under the Hart-Scott-Rodino Act
Del Monte Foods expects the transaction to close in fiscal 2007, subject to the satisfaction of customary closing conditions and antitrust approval under the Hart-Scott-Rodino Act
CVS Corporation (NYSE: CVS) announced today that the waiting period under the Hart-Scott-Rodino Act
(the "HSR Waiting Period") applicable to the pending sale by Albertson's, Inc.
Nasdaq: NUAN) and Dictaphone Corporation today announced that the United States Department of Justice has granted early termination of the antitrust waiting period under the Hart-Scott-Rodino Act
for Nuance's proposed acquisition of Dictaphone.
E[acute accent]--An Overview of the Hart-Scott-Rodino Act
Federal Trade Commission approved early termination of the antitrust waiting period under the Hart-Scott-Rodino Act
for the proposed acquisition of Chiron by Novartis.
Completion of the acquisition is subject, among other matters, to regulatory filings including Hart-Scott-Rodino Act
clearance and is expected to occur in the fourth quarter of 2005.